reports
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
ACN ACCENTURE PLC CLASS A
WK WORKIVA
WDAY WORKDAY INC. CLASS A
THRM GENTHERM INCORPORATED
SXT SENSIENT TECHNOLOGIES CORPORATION
SFM SPROUTS FARMERS MARKETS INC.
NSP INSPERITY INC.
HTGC HERCULES CAPITAL INC.
GPC GENUINE PARTS COMPANY
FELE FRANKLIN ELECTRIC CO. INC.
EXTR EXTREME NETWORKS INC.
EXPE EXPEDIA GROUP INC.
CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION CLASS A
CRY CRYOLIFE INC.
CPRT COPART INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ATRC ATRICURE INC.
STN. STANTEC INC
TLX TALANX AG
FLTR FLUTTER ENTERTAINMENT PLC
BRO BROWN & BROWN INC.
SLM SLM CORP
TREE LENDINGTREE INC.
USLM U.S. LIME & MINERALS
WCN WASTE CONNECTIONS INC.
GIB.A CGI INC. CLASS A
CHWY CHEWY INC. CLASS A
QS QUANTUMSCAPE
SOFI SOFI TECHNOLOGIES INC
BWMN BOWMAN CONSULTING GROUP LTD
TPG TPG INC
SMR NUSCALE POWER CORP
ALAB ASTERA LABS INC
CAI CARIS LIFE SCIENCES INC
PTRN PATTERN GROUP INC.
LCID LUCID GROUP INC.
GDYN GRID DYNAMICS HOLDINGS INC.
APPE1 ASAN PARDAKHT PERSIAN ORD
Macerich Reports Fourth Quarter 2025 Earnings Results
Macerich Reports Fourth Quarter 2025 Earnings Results SANTA MONICA, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Macerich Company (NYSE: MAC) has released its Fourth Quarter 2025 Earnings Results and Supplemental Information by posting it to the Investor Relations section of its website at . As previously announced, management will hold a conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) today, Wednesday, February 18, 2026, to discuss quarterly results. Participants who wish to join the conference by telephone must register using the dial-in registration link below to...
Revolution Medicines to Report Financial Results for Fourth Quarter an...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026 REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, February 25, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a we...
Macerich Declares the Quarterly Dividend on Its Common Shares
Macerich Declares the Quarterly Dividend on Its Common Shares SANTA MONICA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of The Macerich Company (NYSE: MAC) declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on March 30, 2026, to stockholders of record at the close of business on March 16, 2026. About Macerich Macerich (NYSE: MAC) is a fully integrated, self-managed, self-administered real estate investment trust (REIT). As a leading owner, operator, and developer of high-quality retail real estate in densely populated and ...
Macerich Schedules Fourth Quarter 2025 Earnings Release and Conference...
Macerich Schedules Fourth Quarter 2025 Earnings Release and Conference Call SANTA MONICA, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- WHAT: Macerich (NYSE: MAC) Schedules Fourth Quarter 2025 Earnings Release and Conference Call WHEN: Earnings Results will be released after market on Wednesday, February 18, 2026. Management will hold a conference call at 2:00 pm Pacific Time (5:00 pm Eastern Time) on that same day to discuss quarterly results. WHERE: Participants who wish to join the conference by telephone must register using the dial-in registration link below to receive the dial-in nu...
Revolution Medicines to Participate in Guggenheim Securities Emerging ...
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026 REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 9:30 a.m. ET. To listen to a live webcast ...
Revolution Medicines Doses First Patient in Clinical Trial Evaluating ...
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient was dosed in its first-in-human clinical trial evaluating RMC-5127, a RAS(ON) G12V-selective inhibitor. The first-in-human trial, RMC-5127-001 [], is an open-label trial evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activi...
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
CRM SALESFORCE.COM INC.
AXTI AXT INC.
NFLX NETFLIX INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
NTLA INTELLIA THERAPEUTICS INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
GM GENERAL MOTORS COMPANY
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
TSEM TOWER SEMICONDUCTOR LTD
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
SMCI SUPER MICRO COMPUTER
RVMD INC.
AI REVOLUTION MEDICINES
STX C3.AI
GFS SEAGATE TECHNOLOGY HLDGS PLC
QBTS GLOBALFOUNDRIES INC
IONQ D-WAVE QUANTUM INC.
CART IONQ INC
MAPLEBEAR INC.
- Michael Piccolo
Daily Recap: WBD/NFLX,LKQ,SKYT/IONQ, LE,HOLX,GME,BOBS,ONL,CCA,PUM,CRM,...
Warner Bros. Discovery, Inc. (WBD - $28.24) and Netflix Inc. (NFLX - $85.70)News Reports Senate Antitrust Panel Chair Raises Concerns Over Pending Merger. According to the WSJ, Senator Mike Lee, chairman of the Senate Judiciary Committee's Subcommittee on Antitrust, Competition Policy & Consume
- Wedbush Research
TSLA TESLA INC
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
BMRN BIOMARIN PHARMACEUTICAL INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
TSEM TOWER SEMICONDUCTOR LTD
ZM ZOOM VIDEO COMMUNICATIONS INC. CLASS A
SMCI SUPER MICRO COMPUTER
RVMD INC.
STX REVOLUTION MEDICINES
TMC SEAGATE TECHNOLOGY HLDGS PLC
GFS THE METALS COMPANY INC
PL GLOBALFOUNDRIES INC
RGTI PLANET LABS PBC
QBTS RIGETTI COMPUTING INC
IONQ D-WAVE QUANTUM INC.
IONQ INC
- Michael Piccolo
Daily Recap: RVMD/MRK, SKYT/IONQ, USAR, INMD, ETN, RDWR, JHG, LDOS, AA...
SkyWater Technology Inc. (SKYT - $31.32) and IonQ, Inc. (IONQ - $47.25)Announces $1.8 Billion Cash & Stock Acquisition; Offer Value $35.00/share ($15 Cash + $20 Stock, Subject to Collar); Expected Close 2/3Q' 2026. IONQ announced on January 26, 2026, that it has entered into a definitive agreem
- Geoffrey Von Der Ahe
- Michael Piccolo
- Robert Driscoll
- Wedbush Research
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
BIIB BIOGEN INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
RVMD INC.
STX REVOLUTION MEDICINES
GFS SEAGATE TECHNOLOGY HLDGS PLC
EWTX GLOBALFOUNDRIES INC
EDGEWISE THERAPEUTICS INC
- Geoffrey Von Der Ahe
- Robert Driscoll
Macerich Announces Tax Treatment of 2025 Dividends
Macerich Announces Tax Treatment of 2025 Dividends SANTA MONICA, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- The Macerich Company (NYSE: MAC) today announced the tax treatment for dividend distributions taxable in 2025 on its Common Stock. During the calendar year ended December 31, 2025, Macerich paid dividends of $0.68 per share. The 2025 dividends are classified for income tax purposes as follows for The Macerich Company, Common Stock, CUSIP #554382101: Record DatePayable DateRate per Share2025 Taxable Ordinary Dividends2025 Section 199A Dividends*2025 Qualified Dividends*2025 Total Cap...
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
AXTI AXT INC.
NFLX NETFLIX INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
ROKU ROKU INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
PINS PINTEREST INC. CLASS A
SMCI SUPER MICRO COMPUTER
RVMD INC.
CRSR REVOLUTION MEDICINES
RBLX CORSAIR GAMING
STX ROBLOX
TTD SEAGATE TECHNOLOGY HLDGS PLC
GFS THE TRADE DESK
INC.
GLOBALFOUNDRIES INC
- Geoffrey Von Der Ahe
- Robert Driscoll
Revolution Medicines Announces FDA Breakthrough Therapy Designation fo...
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapyFirst Breakthrough Therapy Designation for an investigational drug specifically targeting KRAS G12D mutation in NSCLCRevolution Medicines’ third RAS(ON) inhibitor to receive this designation REDWOOD CITY, Calif., Jan. 08, 2026 (GLOBE NE...
Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare ...
Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 10:30 a.m. PT. To access the live webcast of the presentation, please ...
Revolution Medicines Announces First Patient Randomized in the RASolut...
Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been randomized in the RASolute 304 trial. RASolute 304 is a global, open-label, Phase 3 clinical trial evaluating the safety and efficacy of daraxonrasib, a RAS(ON) multi-selective in...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.